Business
PAVmed Subsidiary Lucid Diagnostics Launches EsoGuard Telemedicine Program in Partnership with UpScriptHealth
Chronic heartburn patients in Phoenix, Denver, Salt Lake City, and Las Vegas can now request video telemedicine physician evaluation and referral for rapid,
About this update from Pavmed Inc.
[{"type":"text","content":"\nChronic heartburn patients in Phoenix, Denver, Salt Lake City, and Las Vegas can now request video telemedicine physician evaluation and referral for rapid, office-based EsoGuard testing to detect esophageal precancer before it progresses to deadly cancer\n\n NEW YORK--(BUSINESS WIRE)--\nLucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced it has launched its EsoGuard Telemedicine Program in partnership with UpScriptHealth, a leading, nationwide, direct-to-consumer telemedicine company.\n\nChronic heartburn patients in four metropolitan areas—Phoenix, Denver, Salt Lake City, and Las Vegas—can now access a Lucid-branded web-based telemedicine platform to request video evaluation of their condition by an independent UpScriptHealth-managed telemedicine physician. If clinically indicated, the patient will be referred to a local Lucid Test Center or other clinical facility offering rapid, office-based testing to detect esophageal precancer using Lucid’s EsoGuard® DNA Esophageal Test (“EsoGuard”). A direct-to-consumer marketing campaign utilizing radio, television, billboards and digital media, will be launched, tested and refined in the Phoenix market before proceeding to other Lucid Test Center cities.\n\n“Many, if not most, chronic heartburn sufferers treat their symptoms without physician supervision using widely available, heavily advertised, over-the-counter heartburn medications—entirely unaware they may be at risk for esophageal precancer and cancer,” said Lishan Aklog M.D., Lucid’s Chairman and Chief Executive Officer. “An important pillar of our growth strategy is to educate consumers on the link between chronic heartburn and esophageal cancer, and the availability of a rapid, office-based test to detect esophageal precancer before it progresses to cancer.”\n\n“The launch of Lucid’s EsoGuard Telemedicine Program is a very important milestone which completes the foundation for our multi-channel EsoGuard commercialization strategy directly targeting primary care physicians (PCPs), gastroenterologists and now consumers. We believe, based on the experience of other successful early cancer detection companies, that telemedicine programs with direct-to-consumer engagement ca...